HRT for Dementia Prevention in Early Onset Menopause

Introduction to HRT in Premature Menopause

The American College of Obstetricians and Gynecologists recommends that women with premature ovarian failure (early onset menopause before age 40) should initiate HRT immediately and continue until at least age 51 to prevent long-term health consequences, including potential cognitive decline 1
Women with premature ovarian insufficiency due to medical treatments, surgery, or spontaneous early menopause should initiate HRT at the time of diagnosis to prevent accelerated cardiovascular disease, bone loss, and other long-term sequelae of premature estrogen deficiency 1

Women with surgical menopause before age 45 have a 32% increased risk of stroke (95% CI, 1.43-2.07) compared to those with natural menopause at typical ages 1
The benefit-risk profile for HRT is highly favorable for women under 60 or within 10 years of menopause onset, including women with premature menopause who should be treated until at least the median age of natural menopause (51 years) 1

The North American Menopause Society recommends initiating HRT immediately upon diagnosis of premature ovarian failure 1
Continue HRT until at least age 51 (median age of natural menopause), then reassess 1
Transdermal estradiol patches (50 μg daily, 0.05 mg/day) should be first-line choice, applied twice weekly 1
For women with intact uterus: Add progestin to prevent endometrial cancer, with micronized progesterone 200 mg daily as the first choice 1

The U.S. Preventive Services Task Force gives a Grade D recommendation (recommend against) for routine HRT use for chronic disease prevention, including dementia prevention, in postmenopausal women 3
The Women's Health Initiative Memory Study in women aged 65-79 years showed that combined estrogen plus progestin increased the risk of probable dementia (HR 2.05, 95% CI 1.21-3.48) 2

Confirm diagnosis of premature ovarian failure (menopause before age 40) or early menopause (age 40-45) 1
Screen for absolute contraindications, including history of breast cancer or hormone-sensitive malignancies, active or history of venous thromboembolism or stroke, coronary heart disease or prior myocardial infarction, active liver disease, antiphospholipid syndrome or positive antiphospholipid antibodies, and unexplained abnormal vaginal bleeding 3, 1

Do not withhold HRT from women with premature menopause due to concerns about dementia risk from WHI trials—those trials studied older women initiating HRT many years after menopause 2, 4
Do not delay HRT initiation in women with surgical menopause before age 45 who lack contraindications—the window of opportunity for cardiovascular and bone protection is time-sensitive 1
Do not use oral estrogen formulations when transdermal options are available—transdermal estradiol has superior safety profile 1
Do not continue HRT beyond age 51-60 solely for dementia prevention—evidence does not support this indication 2, 3